---
layout: default
title: Turoctocog Alfa Pegol
parent: Low Evidence (L4-L5)
nav_order: 675
evidence_level: L5
indication_count: 10
---

# Turoctocog Alfa Pegol
{: .fs-9 }

Tahap bukti: **L5** | Indikasi diramal: **10** 
{: .fs-6 .fw-300 }

---

## Isi kandungan
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Laporan penilaian ahli farmasi

</div>

# Turoctocog Alfa Pegol: From Hemophilia A to Primary Release Disorder of Platelets

## One-Sentence Summary

Turoctocog alfa pegol (DrugBank DB14738) is a PEGylated recombinant Factor VIII replacement product, referenced in the evidence pack as approved for congenital Factor VIII deficiency (Hemophilia A). The TxGNN model predicts it may be effective for **Primary Release Disorder of Platelets**, but this direction is currently supported by **0 clinical trials** and **0 publications**, and the model's own mechanistic annotation flags no direct pharmacological link between the two conditions.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not formally recorded in this dataset (`original_indications` is empty; NPRA license indication text is also blank). Rationale text elsewhere in the pack identifies the drug class as congenital Factor VIII deficiency (Hemophilia A) replacement therapy. |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.9966% |
| Evidence Level | L5 (model prediction only, no clinical or literature support) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for turoctocog alfa pegol is flagged as a data gap in this evidence pack (DG002, High severity). Based on the information that is available, several of the model's own rationale annotations describe the drug as a PEGylated recombinant Factor VIII replacement therapy, indicated for congenital Factor VIII deficiency (Hemophilia A) — a coagulation-cascade disorder corrected by exogenous clotting-factor replacement.

Primary release disorder of platelets, however, is a platelet **function** defect (impaired granule release, e.g. delta/alpha storage pool disease), not a coagulation-factor deficiency. The evidence pack's own mechanistic annotation for this candidate states explicitly that there is "no direct mechanistic association" between platelet granule-release pathology and Factor VIII replacement. This suggests the very high TxGNN score most likely reflects graph-topology proximity between platelet disorders and coagulation disorders in the knowledge graph, rather than a substantiated pharmacological rationale.

Given this, the prediction should be read as a hypothesis-generation signal rather than a mechanistically grounded candidate, consistent with the L5 evidence level and Hold recommendation already assigned in the source data.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Malaysia Market Information

NPRA records show turoctocog alfa pegol as marketed in Malaysia with **4 active registrations**. However, individual license details (authorization numbers, product names, dosage forms, approved indication text) are not populated in the current dataset and cannot be tabulated.

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: `key_warnings`, `contraindications`, and DDI data are all unavailable in this evidence pack — DG001, Blocking severity — which by itself prevents progression to the S1 safety pre-assessment stage.)*

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by the TxGNN model score (L5, no clinical trials or literature), and the evidence pack's own mechanistic annotation indicates no direct pharmacological link between Factor VIII replacement and platelet granule-release disorders. A Blocking-severity data gap (TFDA/NPRA label warnings and contraindications) also prevents any safety pre-assessment at this time.

**To proceed, the following is needed:**
- TFDA/NPRA package insert (warnings, contraindications) — required before any safety pre-assessment (DG001, Blocking)
- Confirmed mechanism of action from DrugBank or primary literature (DG002, High)
- Confirmed original indication text (currently missing from both `original_indications` and NPRA license records)
- Complete Malaysia license details (authorization numbers, product names, dosage forms)
- Independent preclinical or mechanistic evidence specifically linking Factor VIII pathway activity to platelet granule-release physiology, before any clinical exploration is considered
## Penafian

Kandungan ini adalah untuk tujuan penyelidikan sahaja dan bukan nasihat perubatan.
Pengesahan klinikal diperlukan sebelum sebarang aplikasi klinikal.

---

